Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity - PubMed (original) (raw)

Clinical Trial

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

Chao-Hua Chiu et al. Lung Cancer. 2005 Jan.

Abstract

Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer (NSCLC); however, its role in patients with brain metastases has not been clearly defined. We had conducted a prospective study to give gefitinib to NSCLC patients irrespective of their performance status (PS), number of prior treatment regimens and the presence of brain metastases. A total of 76 patients were enrolled. Fifty-seven patients had measurable lesions and the objective response rate was 33.3% (95% confidence interval [95% CI], 20.7-46.0%). For all enrolled patients, the disease control rate was 63.2% (95% CI, 52.1-74.3%) with a median progression-free survival of 5.0 months (95% CI, 3.6-6.5 months) and median overall survival 9.9 months (95% CI, 4.9-14.8 months). Twenty-one patients had simultaneously assessable intracranial lesions (ICLs) and extracranial lesions (ECLs), 17 of them (81.0%) showed comparable tumor response. There was no survival difference between the patients with and without metastatic brain disease. Most drug-related adverse events were mild. Intolerable toxicities happened in five patients, four of them were interstitial pneumonia (5.8%). Severity of skin toxicity was tightly associated with tumor response and patient survival (P = 0.007 and <0.001) and the association was consistent in the analysis using early toxicity profile (P = 0.033 and 0.001). In conclusion, gefitinib is active in patients with brain metastasis from NSCLC and tumor response is related to skin toxicity. It is feasible to conduct randomized trials to identify the role of gefitinib alone or in combination with other modality for treatment of NSCLC patients who have metastatic brain lesion(s).

PubMed Disclaimer

Similar articles

• Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
  Hotta K, Kiura K, Ueoka H, Tabata M, Fujiwara K, Kozuki T, Okada T, Hisamoto A, Tanimoto M. Hotta K, et al. Lung Cancer. 2004 Nov;46(2):255-61. doi: 10.1016/j.lungcan.2004.04.036. Lung Cancer. 2004. PMID: 15474674 Clinical Trial.
• [Gefitinib is active in patients with brain metastasis from non-small cell lung cancer].
  Tsai C, Chiu C, Liou J, Tsai P, Perng R. Tsai C, et al. Zhongguo Fei Ai Za Zhi. 2004 Aug 20;7(4):298-304. doi: 10.3779/j.issn.1009-3419.2004.04.07. Zhongguo Fei Ai Za Zhi. 2004. PMID: 21241546 Chinese.
• Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
  Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, Takeda Y, Kimura H, Okada T, Yamaguchi T, Nakagawa M, Okumura Y, Maeda H, Ito M. Namba Y, et al. Clin Lung Cancer. 2004 Sep;6(2):123-8. doi: 10.3816/CLC.2004.n.026. Clin Lung Cancer. 2004. PMID: 15476598 Review.
• A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
  Park K, Goto K. Park K, et al. Curr Med Res Opin. 2006 Mar;22(3):561-73. doi: 10.1185/030079906X89847. Curr Med Res Opin. 2006. PMID: 16574039 Review.

Cited by

• Systemic therapy of brain metastases.
  Brastianos HC, Cahill DP, Brastianos PK. Brastianos HC, et al. Curr Neurol Neurosci Rep. 2015;15(2):518. doi: 10.1007/s11910-014-0518-9. Curr Neurol Neurosci Rep. 2015. PMID: 25492479 Review.
• Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
  Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, Song Y. Liu HB, et al. PLoS One. 2013;8(1):e55128. doi: 10.1371/journal.pone.0055128. Epub 2013 Jan 30. PLoS One. 2013. PMID: 23383079 Free PMC article. Review.
• EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data.
  Fan Y, Xu X, Xie C. Fan Y, et al. Onco Targets Ther. 2014 Nov 10;7:2075-84. doi: 10.2147/OTT.S67586. eCollection 2014. Onco Targets Ther. 2014. PMID: 25419145 Free PMC article.
• Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases.
  Cai L, Qiu X, Yang H, Lai M, Shan C, Hong W, Li J, Luo L, Zhang P, Wang L. Cai L, et al. Oncotarget. 2016 Jul 6;8(34):57470-57476. doi: 10.18632/oncotarget.10420. eCollection 2017 Aug 22. Oncotarget. 2016. PMID: 28915686 Free PMC article.
• A real-world study in advanced non-small cell lung cancer with de novo brain metastasis.
  Lei L, Wang WX, Wang D, Lin L, Zhu YC, Wang H, Wang LP, Zhuang W, Fang MY, Wan B, Feng HJ, Xu CW. Lei L, et al. J Cancer. 2021 Jan 1;12(5):1467-1473. doi: 10.7150/jca.51411. eCollection 2021. J Cancer. 2021. PMID: 33531991 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information